Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders

NCT00686699 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00686699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00686699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Terminated
Start date
July 10, 2006
Completion date
March 6, 2008
Enrollment
11 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

akathisia, drug-induced, dyskinesia, drug-induced, parkinsonian disorders